Article Figures & Data
Figures
- FIGURE 1.
Anterior whole-body scans of patient 9. (A) Scan obtained 24 h after injection of 7,400 MBq of 177Lu-DOTATOC shows several abdominal metastases (liver, spleen, and lymph nodes). (B) Scan obtained 6 h after injection of 185 MBq 111In-Octreoscan 6 mo after treatment with 7,400 MBq of 177Lu-DOTATOC shows a decrease in tumor load. Especially, a reduction of liver metastases can be seen.
- FIGURE 2.
CT scans of patient 9. (A) Nine months after treatment with 90Y-DOTATOC and 4 wk before treatment with 177Lu-DOTATOC, CT scan shows multiple liver metastases. (B) Corresponding CT scan 4 mo after treatment with 177Lu-DOTATOC shows minor response.
Tables
Patient no. Sex Age (y) Diagnosis Date of diagnosis Classification 3 mo after 90Y-DOTATOC Pretreatments (except 90Y-DOTATOC) Number of 90Y-DOTATOC treatments Total dose of 90Y-DOTATOC/m2 Months since last treatment with 90Y-DOTATOC 1 F 71 Neuroendocrine tumor of small bowel Nov 01 Stable disease — 2 200 16 2 M 55 Neuroendocrine tumor of pancreas Jun 97 Partial remission S, Oct, Ch 3 300 11 3 M 63 Neuroendocrine tumor of pancreas Dec 00 Stable disease Ch, INF 2 200 18 4 F 74 Neuroendocrine tumor of appendix Jan 00 Stable disease S 3 200 8 5 F 55 Neuroendocrine tumor of pancreas Feb 01 Partial remission S 2 200 22 6 F 60 Neuroendocrine tumor with unknown primary Dec 99 Partial remission Oct 2 200 16 7 F 59 Neuroendocrine tumor of stomach Nov 00 Minor response S 3 300 10 8 F 51 Neuroendocrine tumor of rectum Aug 95 Partial remission S 2 200 22 9 M 56 Neuroendocrine tumor of small bowel June 02 Partial remission Oct 2 200 9 10 M 60 Neuroendocrine tumor of small bowel Mar 99 Partial remission S 2 200 11 11 F 65 Neuroendocrine tumor of pancreas Dec 98 Partial remission Oct, INF 2 200 10 12 M 38 Neuroendocrine tumor with unknown primary Mar 98 Stable disease Oct, Ch, 186Re-HEDP 3 300 18 13 M 58 Neuroendocrine tumor with unknown primary May 01 Minor response S 2 200 17 14 M 54 Neuroendocrine tumor of small bowel Oct 00 Minor response S 2 200 24 15 M 63 Neuroendocrine tumor of pancreas (insulinoma) Sep 01 Partial remission Oct 2 200 13 16 M 76 Neuroendocrine tumor of pancreas Nov 98 Partial remission S 2 200 32 17 M 49 Neuroendocrine tumor of pancreas Dec 01 Partial remission Oct 2 200 9 18 M 43 Neuroendocrine tumor of pancreas Feb 01 Partial remission S, Ch 3 300 14 19 F 66 Neuroendocrine tumor of pancreas Aug 96 Partial remission S 2 200 22 20 M 49 Neuroendocrine tumor of rectum Jun 00 Partial remission S, Oct, INF 2 200 11 21 F 46 Neuroendocrine tumor of unknown origin, most likely insulinoma Jan 97 Stable disease Oct 3 300 32 22 M 51 Neuroendocrine tumor of small bowel Apr 00 Stable disease S 3 300 5 23 M 65 Neuroendocrine tumor of small bowel Feb 02 Stable disease S 2 200 4 24 F 60 Neuroendocrine tumor of small bowel Oct 99 Stable disease S 3 300 22 25 M 65 Neuroendocrine tumor of bronchus Mar 99 Partial remission Ch 3 300 6 26 M 50 Neuroendocrine tumor of pancreas May 98 Stable disease S, Oct, INF, Ch 2 200 27 27 M 51 Neuroendocrine tumor of pancreas (gastrinoma) Feb 00 Stable disease S 2 200 8 S = surgery; Oct = octreotide (long- or short-acting) or lanreotide; Ch = chemotherapy; INF = interferon.
Patient no. Hemoglobin (g/L) Thrombocytes (×109/L) Creatinine (μmol/L) Clinical result after treatment with 177Lu-DOTATOC Before 90Y-DOTATOC treatment Before 177Lu-DOTATOC treatment After 177Lu-DOTATOC treatment Before 90Y-DOTATOC treatment Before 177Lu-DOTATOC treatment After 177Lu-DOTATOC treatment Before 90Y-DOTATOC treatment Before 177Lu-DOTATOC treatment After 177Lu-DOTATOC treatment 1 104 87 72 406 372 206 83 133 118 Stable disease 2 116 102 105 176 188 143 77 117 124 Stable disease 3 133 115 115 302 251 122 68 94 62 Progressive disease 4 116 115 108 285 188 200 60 111 75 Progressive disease 5 127 119 116 129 173 95 52 65 70 Partial remission 6 107 107 109 311 152 133 54 59 62 Stable disease 7 115 100 102 268 239 108 33 60 63 Progressive disease 8 133 116 115 218 303 190 45 58 43 Minor response 9 145 137 116 226 182 132 74 96 97 Minor response 10 135 134 115 218 214 329 61 58 68 Minor response 11 111 110 112 679 299 127 57 62 61 Minor response 12 136 123 128 227 462 252 61 84 82 Stable disease 13 126 127 112 275 234 208 71 88 84 Progressive disease 14 160 140 135 243 244 219 71 96 114 Progressive disease 15 110 105 80 348 187 109 65 197 167 Partial remission 16 141 109 104 241 282 241 70 137 112 Stable disease 17 146 131 130 279 245 239 88 90 102 Minor response 18 149 102 114 455 366 215 69 120 104 Stable disease 19 124 129 129 521 334 243 49 51 64 Stable disease 20 140 128 126 404 158 138 77 128 111 Stable disease 21 134 100 101 237 329 283 57 248 269 Stable disease 22 144 114 123 339 409 342 81 88 120 Progressive disease 23 146 123 118 231 162 157 65 73 71 Stable disease 24 137 103 118 218 225 186 78 101 97 Progressive disease 25 134 137 136 301 300 267 91 145 147 Stable disease 26 138 125 127 181 222 138 77 67 70 Progressive disease 27 134 114 105 544 378 303 49 79 49 Stable disease Mean ± SD 131 ± 14 117 ± 13 114 ± 14 306 ± 123 263 ± 82 197 ± 70 66 ± 14 100 ± 44 97 ± 45
In this issue
Jump to section
Related Articles
Cited By...
- Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities
- Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy
- Parametric Net Influx Rate Images of 68Ga-DOTATOC and 68Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast
- Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
- Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging
- Radiopeptide Imaging and Therapy in Europe
- Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours
- Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
- Dynamic and Static Small-Animal SPECT in Rats for Monitoring Renal Function After 177Lu-Labeled Tyr3-Octreotate Radionuclide Therapy
- Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
- 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
- Electron- and Positron-Emitting Radiolanthanides for Therapy: Aspects of Dosimetry and Production